Key result
Enalapril increased reported side effects compared to placebo (28.1% vs 16.0%, p<0.0001) and led to higher therapy discontinuation (15.2% vs 8.6%, p<0.0001) in patients with LVD.
Authors
Loading...
Clinicians should anticipate higher discontinuation when starting enalapril in LVD; confirms ACEI tolerability burden in randomized settings.
RCT (n=6,797)
Double-blind
Absolute Event Rate: 28.1% vs 16%
p-value: p=< 0.0001
Kostis et al. (1996) conducted an RCT in Left Ventricular Dysfunction (n=6,797). Enalapril vs. Placebo was evaluated on Reported side effects (p=< 0.0001). Enalapril increased reported side effects compared to placebo (28.1% vs 16.0%, p<0.0001) and led to higher therapy discontinuation (15.2% vs 8.6%, p<0.0001) in patients with LVD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: